Skip to main content

Borregaard ASA: EBITDA1 of NOK 440 million in the 3rd quarter

Borregaard’s operating revenues were NOK 1,799 million (NOK 1,949 million)2 in the 3rd quarter of 2025. EBITDA1 was NOK 440 million (NOK 524 million). The result in BioSolutions increased while BioMaterials and Fine Chemicals had lower results compared with the 3rd quarter of 2024.

The reduced EBITDA1 was due to lower bioethanol prices and the temporary disruption in cellulose production at the Sarpsborg site. The negative impact from this disruption amounts to approximately NOK 40 million. The improvement in the result for BioSolutions was attributable to sustained growth in sales to agriculture. In BioMaterials, higher sales prices were more than offset by lower sales volume. Fine chemical intermediates delivered a strong result. Net currency effects were positive across all areas.

Profit before tax was NOK 247 million (NOK 326 million). Earnings per share were NOK 1.96 (NOK 2.51).

We are pleased with the strong development in agricultural sales and our ability to deliver solid results during uncertain global conditions. This demonstrates the strength and flexibility of Borregaard’s business model, says CEO Tom Erik Foss-Jacobsen.

Contacts:
CFO Per Bjarne Lyngstad, +47 952 44 515
Director Communications, Tone Horvei Bredal, +47 924 67 711

1. Operating profit before depreciation, amortisation and other income and expenses
2. Figures in parentheses are for the corresponding period in the preceding year

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5 – 12 of the Norwegian Securities Trading Act.

This stock exchange announcement was published by Lotte Kvinlaug, Investor Relations Officer at Borregaard ASA, on 22 October 2025 at 07:00 CEST.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.